IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to show that non-steroidal treatment with intravenous
immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous
lupus erythematosis (CLE) patients.
Phase:
Early Phase 1
Details
Lead Sponsor:
University of California, Irvine
Collaborators:
Grifols Therapeutics Inc. Grifols Therapeutics LLC